Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AB ScienceABSCF 53 Equity-to-Asset is -0.70 as of Dec. 2025. GuruFocus rates ABSCF with a GF Score™ of 53/100 and a GF Value™ of $2.26. The stock has 11 warning signs investors should review. Among 1,007 Drug Manufacturers companies, AB Science ranks worse than 94.94% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. AB Science's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $-20.14 Mil. AB Science's Total Assets for the quarter that ended in Dec. 2025 was $28.72 Mil.
Therefore, AB Science's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was -0.70.
The historical rank and industry rank for AB Science's Equity-to-Asset or its related term are showing as below:
ABSCF'
s Equity-to-Asset Range Over the Past 10 Years
Min: -1.51 Med: -0.76 Max: 0.21
Current: -0.7
During the past 13 years, the highest Equity to Asset Ratio of AB Science was 0.21. The lowest was -1.51. And the median was -0.76.
ABSCF's Equity-to-Asset is ranked worse than 94.94% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs ABSCF: -0.70
AB Science (OTCPK:ABSCF) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
AB Science Equity-to-Asset Related Terms
AB Science Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for AB Science's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABSCF vs ZTS, UTHR, VTRS: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, AB Science's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AB Science Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AB Science's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where AB Science's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
AB Science's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AB Science (ABSCF) has a Equity-to-Asset of -0.70 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on AB Science and its competitors. According to the industry distribution chart, AB Science ranks #956 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 94.9%.
Is AB Science's Equity-to-Asset too high?
AB Science's current Equity-to-Asset is -0.70. Based on the distribution chart, AB Science ranks #956 out of 1007 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, AB Science has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does AB Science's Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, AB Science ranks #956 out of 1007 companies for Equity-to-Asset. This places AB Science in the lower half of its industry. The industry median Equity-to-Asset is 0.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on AB Science and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AB Science's current Equity-to-Asset is -0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AB Science stock overvalued right now?
AB Science (ABSCF) has a current Equity-to-Asset of -0.70. The stock's GF Value™ is $2.26, compared to a current price of $1.12 — trading 50.4% below its estimated fair value. The current Equity-to-Asset is -0.70. AB Science's overall GF Score™ is 53/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For AB Science (ABSCF), the current Equity-to-Asset is -0.70 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AB Science (ABSCF) Overvalued in 2026?
Based on GuruFocus' analysis, AB Science stock appears to be undervalued.
The current stock price of $1.12 is trading 50.4% below its estimated GF Value™ of $2.26.
Key valuation signals for ABSCF:
Equity-to-Asset: -0.70
GF Value™: $2.26 vs. price of $1.12 (50.4% below fair value)
No single metric tells the full story. See the ABSCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AB Science is a clinical-stage pharmaceutical company that has developed a diversified portfolio of medicines targeting unmet medical needs, based on two platforms. Masitinib platform: It is based on masitinib, a selective protein kinase inhibitor in development for neurodegenerative diseases, oncology, & inflammatory diseases. It has the clinical development of masitinib in neurodegenerative diseases (specifically Alzheimer's disease, amyotrophic lateral sclerosis, & progressive forms of multiple sclerosis). ALDH/Microtubule Platform: It is a portfolio of synthetic agents that target cancer cells by destabilising microtubules, which are essential for cell division & cancer stem cells, by inhibiting enzymes that are essential for maintaining their physiological state & survival.
53GF Score
Get the complete analysis for ABSCF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABSCF has been successfully added to your 
